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Abstract
Background: Little is known about the impact of the recent varicella vaccine shortage. To assess
the temporal trend in varicella vaccine administration before 18 and 24 months of age in a
community cohort of children prior to, during and after the recent varicella vaccine shortage. And
to compare the temporal trends in varicella vaccinations to trends of an older, more widely
accepted vaccine, the MMR.
Methods: Community population-based birth cohorts were identified who were eligible for the
varicella vaccination before, during and after the 2001 to 2002 varicella vaccine shortage. Only
children (84% of all) who remained in the community through their second birthday were included.
For each child in the cohort, the medical records and immunization registry records from both
medical facilities in the county were reviewed to identify the dates and sites for all varicella
immunizations given. In addition to varicella immunizations, the dates of all MMR vaccinations were
recorded. Additional data abstracted included the child's birth date, gender and dates of any
recognized cases of chickenpox up through age 24 months.
Results: Of the 2,512 children in the birth cohorts, 50.8% were boys. In the three cohorts
combined, 81.1% of the boys and 79.3% of the girls (p = 0.30) received the varicella vaccine by age
24 months. The pre-shortage community rate of varicella immunization was 79.7% by 24 months
of age. During the varicella vaccine shortage, the rate of varicella immunization by 24 months fell
to 77.2%. Only 6 additional children received a "catch-up" immunization by 36 months of age. In
the post shortage period the community 24-month immunization rate rebounded to a level higher
than the pre-shortage rate 84.0%. During the almost three years of observation, the MMR
immunization rate by age 24 months was constant (87%).
Conclusion: The varicella shortage was associated with an immediate drop in the 24-month
varicella immunizations rate but rebounded quickly to above pre-shortage rates. In this community
the only long term impact of the varicella vaccine shortage may be on the small number of children
who still had not received catch-up varicella immunizations by 36 months of age.
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Background
Varicella vaccine is a relatively new vaccine that has
incomplete but growing acceptance by physicians and
parents [1-3]. Currently more physicians recommend the
use of varicella vaccine than 5 years ago[4], and more
schools and day care sites are requiring receipt of the vac-
cine for admission[5]. However, the recent extended
period of varicella vaccine shortage resulted in temporary
modifications of the recommended age for vaccine
administration and easing of some requirements for vac-
cine administration prior to school and day care program
entrance[6]. It is not known if this "relaxing" of varicella
vaccine requirements will affect clinician's or parent's
future acceptance of varicella immunizations or alter the
strength of their belief in the benefit of this vac-
cine[1,2,4,7,8].
The short and long term effects of a vaccine shortage on
the rates of a relatively newer vaccine, the varicella vaccine
are unknown. Two of the potential short term effects may
be an immediate increase in the incidence of the target
disease and a failure to provide catch up immunizations
leaving a group of children at longer term risk of the target
disease. To bolster efforts to provide catch-up immuniza-
tions, recommendations for developing recall and
reminder programs were distributed through the MMWR
and professional medical societies such as the American
Academy of Family Physicians[9] and the American Acad-
emy of Pediatrics[10]. The shortage of vaccine may also
have a longer term impact on decreasing future vaccine
acceptance and usage, especially for a vaccine such as vari-
cella that was still in the adoption phase by many parents
and clinicians at the time of the shortage[1,2,7,11-17].
Clinicians and parents might feel that the approved delay
in the administration of the varicella vaccine suggests it is
of lesser value than another vaccine (MMR) that was also
in short supply but did not have any modifications for
timing of vaccine administration for the first dose or relax-
ing of requirements for vaccination prior to school entry.
The vaccine shortage may therefore affect not only provi-
sion of the vaccine during the shortage period but may
also decrease or delay administration of the varicella vac-
cine even after correction of the shortage (longer term
effect).
This study addresses the temporal trend in rates of up-to-
date varicella immunizations at ages 18 and 24 months in
birth cohorts eligible for a varicella and MMR vaccine
before, during, and after the varicella shortage period in
2001 and 2002. To place the temporal trends in context,
the varicella immunization rates were compared to
immunization rates of an older and more widely accepted
vaccine, the MMR, that had a similar but less marked
shortage problem at about the same time.
Methods
Population studied
After approval was received from the Olmsted Medical
Center and Mayo Clinic Foundation Institutional Review
Boards, all members of three birth cohorts within Olm-
sted County, Minnesota were selected as subjects for this
study. Olmsted County, Minnesota was selected because it
has a population-based database that includes all births to
Olmsted County residents and all of the health care serv-
ices, including immunizations used by all members of
those birth cohorts. The database includes birth informa-
tion on 99.5% of all births and health care information on
98% of the residents of the county and covers 98% of the
care they receive[18]. The racial diversity of Olmsted
County has significantly changed in the past 5 years. Cur-
rently the racial and ethnic characteristics of the children
born to Olmsted County residents include 65% white
non-Hispanic children, 5% Hispanic children, 18% Afri-
can or Black and 12% Asian (personal communication
Division of Health Statistics, Minnesota Department of
Health, May 2004). Overall, 23.6% of all children born in
Olmsted County to Olmsted County residents are cur-
rently receiving Medicaid. Another 15% are covered under
the Minnesota subsidized health insurance program, Min-
nesotaCare.
Because the exact date of the beginning and end of the
varicella vaccine shortage period was known for the
health care clinics in Olmsted County, Minnesota
(December 2001 through August 2002), it was possible to
tailor the pre-shortage, intra-shortage and post-shortage
birth cohorts to exactly match the shortage period. The
birth cohorts correspond to children eligible for the vari-
cella vaccine prior to the shortage (the children who were
at 18 to 30 months of age at the beginning of the shortage,
December 1, 2001), children primarily eligible for vari-
cella immunization during the shortage (all those who
reached 12 months of age during the shortage) and chil-
dren eligible for varicella immunization after the resolu-
tion of the shortage (those who reached 12 months of age
after the resolution of the shortage). These three birth
cohorts were studied separately to identify up-to-date vari-
cella immunizations by 18 and 24 months of age. The
children who were 12 to 18 months during the shortage
period were followed out to 36 months of age to see if late
catch up immunizations occurred. Children who moved
into the community after birth were not included since we
had no way of determining the exact age when they
entered the community, only when they first accessed
health care.
The setting
Olmsted County is a metropolitan statistical area sur-
rounded by rural agricultural communities and is 90
miles south of the twin cities of Minneapolis and St Paul.
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The population is relatively isolated from other urban
centers and its inhabitants therefore obtain almost all of
their primary and tertiary medical care within the metro-
politan area of Rochester, Minnesota[18]. The community
is unique in that it is relatively isolated and has only two
major health care providers both with records that are
linked by the diagnostic index of the Rochester Epidemi-
ology Project (REP) that can provide all medical record
identifiers for all care used by any child born in Olmsted
County.
Children were cared for by 124 family medicine and pedi-
atric physicians and 23 Advance Practice Nurses whose
demographics are comparable to those of all non-aca-
demic based U.S. primary care physicians (AMA master
file, 2002). In Olmsted County the private medical groups
were unable to obtain any new doses of varicella vaccine
beginning December 1, 2001. The shortage abated in one
site by May 6, 2002 but not until August 31, 2002 in the
other. MMR vaccine had limited availability only between
February 1, 2002 and April 15, 2002. The usual care pro-
cedure for both of the two large clinics in Olmsted
County, Minnesota (the Mayo Clinic and the Olmsted
Medical Center) is to administer the varicella and MMR
vaccines simultaneously at 12 to 14 months of age. In the
two years preceding the shortage, 80% of varicella immu-
nizations given by 24 months of age were given between
11.5 and 14 months of age and 90% by 15 months of age.
Varicella immunization is recommended between 12 and
18 months of age and the MMR between 12 and 15
months of age[5].
Data collection
All information for this study was collected from the med-
ical records and the immunization registries of the two
medical clinics in the county. The information collected
included: child's name, mother's maiden name, birth
date, gender, date of varicella immunization, date of vari-
cella infection, date of MMR immunization and date of
last medical visit in the community. The child's name and
mother's name were necessary since children often
received care in more than one site, and children's names
may change due to marriage or divorce but the mother's
maiden name is stable.
Data analysis
Basic descriptive statistics were used to provide unad-
justed immunization rates, calculated separately for each
of the 3 cohorts (before, during and after) with binomial
confidence intervals. Graphical and tabular summaries
are presented.
The primary tool for formal comparison of immunization
rates across the three time periods was logistic regression
modeling. The response variable was whether or not a
child born in Olmsted County in the specified time period
of the birth cohort is or is not known to have received vari-
cella vaccination by age 18 (and 24) months. Predictor
variables included the time period defining the cohort
(before shortage, during shortage or after shortage), and
principal site of care. Joint modeling and comparison of
MMR and varicella immunization rates was carried out
using Generalized Linear Mixed Models (GLMM), adjust-
ing for multiple MMR or varicella immunizations per
child. Temporal trends over the birth cohorts were tested
using linear and quadratic orthogonal polynomials. A
rebound in the vaccination rate corresponds to a signifi-
cant positive coefficient for the quadratic trend, i.e. a bend
departing from a linear time trend. Differences in age at
immunization were tested using Wilcoxon rank-sum tests.
No formal comparisons between immunization rates at
the two large institutions were allowed by either IRB of
record.
Results
A total of 2,512 children were included in the 3 cohorts
after removing those who died before age 12 months (n =
25) and those who had primary chickenpox prior to age
18 months (n = 18) (Table 1). The group included slightly
more boys (50.8%) than girls (49.2%). Two thirds of the
children were born in one of the health system's hospitals
and 1/3 in the other.
The 18 children removed due to primary varicella infec-
tion included a total of 17 children (9 boys and 8 girls)
who had documented chickenpox prior to age 12 months,
and another boy between 12 and 18 months of age.
Between 18 and 24 months only 3 cases of chickenpox
were documented in the medical records. Only 1 of these
3 cases of chickenpox occurred during the period of vac-
cine shortage suggesting that no large number of cases of
chickenpox occurred during the vaccine shortage.
The composite rate for varicella vaccination by age 24
months in the three cohorts of children was 82.3%. Of the
Table 1: Number and gender distribution of children in each phase of the study.
Gender "Pre-shortage" birth cohort During shortage birth cohort Post-shortage birth cohort
Male 742 261 272
Female 726 248 263
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1275 boys in the three cohorts, 231 of them received no
documented varicella immunization, 24 received a vari-
cella vaccination only after 24 months of age and 81.0%
were immunized by 24 months of age. Boys were slightly
but not statistically significantly more likely to receive vac-
cine for varicella than girls (OR 1.06, p = 0.27). Of the
1237 girls, 343 were not immunized, 33 were immunized
after 24 months and 80.4% of those eligible were immu-
nized between birth and 24 months of age.
The temporal pattern of varicella vaccination rates at age
18 and 24 months did not vary between the two major
health care institutions. Both sites demonstrated the antic-
ipated decline in varicella immunization rates during the
shortage, rebounding after the shortage (p = .035). How-
ever the decline was greater (6.2%) for the institution that
experienced a longer period (9 months, December 2001
through August 2002) of inability to obtain varicella vac-
cine compared to the institution that experienced only a
4-month period (December 2001 through March 2002)
of shortage (0.7% decline).
Not all of the children who failed to receive a varicella
immunization during the shortage period had a catch-up
immunization by 24 or even by 36 months of age. During
the varicella vaccine shortage, the rate of varicella immu-
nization by 18 months fell from 78.1% to 75.2% (p =
0.04). An additional 2% of children in the "shortage
cohort" had a catch up immunization between 18 and 24
months of age (varicella immunization rate at 24 months
was 77.2%, lower than the pre-shortage 24 month immu-
nization rate of 80.6%, p > 0.05). But of the 127 children
who did not receive a catch-up immunization by 24
months, only 6 more received a later "catch-up" immuni-
zation by 36 months of age.
In both institutions the varicella immunization up to date
rate for children 18 and 24 months rebounded in the
post-shortage period. In the institution experiencing the
longer shortage, the rate had not yet returned to the pre-
shortage rate at the end of the observation period (Figures
1 and 2).
In an unexpected result, the data indicated that children
who received the varicella vaccine in the post-shortage
period were being immunized at a slightly younger age
than during the pre-shortage period (p < .0001) (Figure
3). For children immunized between 12 and 18 months
of age, the mean age at varicella immunization decreased
from 395.2 days for the pre-shortage cohort to 386.8 days
for the post-shortage cohort. Although the average differ-
ence is unlikely to be clinically significant, this group
includes 18 children immunized more than 4 weeks
before attaining 12 months of age. Of these 18, only two
were revaccinated during the required age range.
As expected, the MMR immunization rates by both ages
18 and 24 months were higher than varicella immuniza-
tion rates at similar ages during all periods studied (p <
.0001) (Figures 1 &2). The rate of MMR immunization by
age 18 months declined slightly in the post varicella short-
age period but was stable by the time children were 24
months of age suggesting that the MMR shortage may
have resulted in a slight delay in MMR administration to
past 18 months of age in a small group of children.
Discussion
As anticipated, the varicella vaccine shortage period was
associated with an immediate negative but small impact,
a decline in the varicella immunization rate appearing not
24-month vaccination ratesFigure 2
24-month vaccination rates. Rate of up to date varicella 
and MMR immunizations at age 24 months in three cohorts.
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18-month vaccination ratesFigure 1
18-month vaccination rates. Rate of up to date varicella 
and MMR immunizations at age 18 months in three cohorts.
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only in the immediate shortage period but persisting up to
36 months of age in the children who were primarily eli-
gible for the varicella vaccine during the shortage period.
However, the decline in use of varicella vaccine
rebounded following the resolution of the shortage.
Therefore, the long-term impact would appear to be lim-
ited to any negative longer-term effects for the modest
increase in percent of children who were not immunized
during the shortage period and did not have catch-up
immunizations by 36 months of age compared to birth
cohorts before and after the shortage period. This could
result in an increase in primary varicella infections or later
herpes zoster in this group of children. However, the rate
of immunization even in this group did not fall below
70%, which may be sufficient to provide good "herd"
immunity[16]. The rate of MMR immunization by 24
months was stable throughout the period of observation.
No increase in primary varicella infection rates were seen
during the shortage period.
The immediate negative impact on immunizations given
to 12 to 18 month old children during the shortage was
anticipated nationally and even resulted in modifications
of the requirements for varicella immunization prior to
day care and school admission for the state of Minnesota.
The incomplete catch-up of varicella immunizations in
the group that were unable to receive immunizations dur-
ing the "usual" immunization age period is also not unex-
pected. The impact on the varicella immunization rate in
the cohort following resolution of the shortage is of spe-
cial interest since these children will require immuniza-
tion before school entry at age 5 or 6 years but will remain
susceptible until that time. Following resolution of the
shortage, the varicella immunization rate returned to pre-
shortage baseline rates in the entire community but
required about 6 months to rebound. It appeared that the
rebound returned to the trajectory of overall increase of
varicella vaccinations to children 12 to 18 months of age.
This increasing trajectory has been seen throughout the
U.S. [16]. The other interesting difference is the decline in
the average age of the varicella immunization. This
appears to parallel the younger age at which the MMR is
administered. The implications of this may be that chil-
dren are making a 12-month "well baby visit" and receiv-
ing immunizations. This could be accompanied by a
decline in the rate of "well baby" visits at 15 and 18
months since no further immunizations are required. This
deserves further study.
Vaccines given too early may not be effective due to inter-
ference with maternal antibodies. The ACIP, AAFP, and
AAP have published guidelines on the timing of child-
hood immunizations[19,20]. One study found that 8% of
children received at least 1 vaccination dose too early to
be considered valid[21]. Our data shows approximately
9% of children vaccinated with varicella vaccine prior to
age 12 months.
These study data show that a catch-up varicella immuni-
zation process did occur following resolution of the short-
age. A group of children (n = 29) received the varicella
vaccine between 18 and 24 months, which is later than
recommended by the ACIP. Only a few additional chil-
dren (n = 6) received a late catch-up varicella immuniza-
tion between 24 and 36 months. This suggests that the
recall and reminder systems were not entirely successful in
reminding physicians or convincing parents to bring their
children back for the immunization. With the current data
it is impossible to know which occurred. The benefits of
immunization registries in increasing and maintaining
higher immunization rates have been well documented in
the medical literature [22-26] [Meriwether RA: Proposal
for development of a North Carolina immunization regis-
try and plans to improve preschool immunization levels,
submitted]. Nothing has been published about the actual
functioning of immunization registries in providing
"catch-up" immunizations following resolution of a vac-
cine shortage. These data suggest that studying the func-
tioning of immunization registries in these post-shortage
periods could provide important and useful insight into
the strengths and weakness of existing immunization reg-
istry designs. Do clinicians use the catch-up features of the
immunization registries? Are registries adequately
designed and equipped to deal with a vaccine shortage or
do parents fail to respond to recall or reminder letters
once the vaccine shortage is resolved? Solutions are poten-
tially available for each of the proposed problems but the
solutions are likely to be very different. This should be fur-
ther studied.
Survival plots showing time to Varicella Vaccination for 3 birth cohorFigure 3
Survival plots showing time to Varicella Vaccination 
for 3 birth cohorts. Comparisons of age at time of varicella 
vaccination in three birth cohorts.
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The stable rate of MMR immunization was anticipated. In
the past, the MMR has been more widely accepted by phy-
sicians and nurses and parents than the varicella vac-
cine[1,3]. However, the trajectory of increasing varicella
vaccination among all US children (varicella coverage
increased from 76% in 201 to 85% in 2003[27]) and the
children in this county, shows that by early 2004, the rates
of varicella and MMR immunizations are closer than they
were in 2001 (3% difference rather than a 6% difference).
By 2010, both immunization rates may be close to the
Healthy People 2010 goal of 90%[28].
The population in this study is predominantly Caucasian
(about 85% white, non-Hispanic). Previous comparison
of population-based up-to-date immunization rates in
Olmsted County with those from other communities
within the US suggest that the findings from Olmsted
County immunization studies can be generalized to a
large portion of the U. S. population[29]. While caution
should be used when generalizing from any single popu-
lation to that of others, the ability to include an entire
community and all primary care physicians and providers
rather than the population of a single institution is a
major strength of using this community for this study. It
is possible that immunizations were obtained at other
sites outside the county and therefore we may have under-
estimated the vaccination rate during the shortage. How-
ever, the entire region of SE Minnesota was experiencing
the same shortage and only children taken to other
regions of the state or the country would have any greater
access to the vaccine. In addition, the local vaccine regis-
tries attempt to collect data on "outside" immunizations.
The National Immunization Survey (NIS) also collected
data from samples of children in counties throughout the
US to assess the impact of the varicella vaccine shortage.
However, the NIS had to combine information from
many counties since only a few children per county were
sampled. This made it difficult to identify associations
between the varicella immunization rates and the availa-
bility of the vaccine since even adjoining counties often
had different levels and durations of varicella vaccine
shortage. Therefore, the data from the NIS cannot identify
differences in immunization rates based on the severity or
duration of the shortage in the county in which the sub-
jects reside. It would be very helpful to have data similar
to the data presented here to understand the patterns of
impact of the varicella shortage in other areas of the coun-
try.
Conclusion
The varicella vaccine shortage was associated with a small
decline in varicella immunization rates during the short-
age period. However, the varicella vaccination rate
rebounded to pre-shortage rates and appears to continue
to be on an upward trend post-shortage.
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